Semaglutide and Liraglutide are longer-acting, which means they provide steady appetite regulation and blood sugar support
This study is not intended to break the bubble of hope but to add a layer of precaution in their over-prescription. The study serves as a critical reminder that while these medications can provide significant health benefits, their potential risks warrant careful scrutiny and further research
S., Gridley G., McLaughlin J
Metabolic syndrome associates with a higher PDAC risk [4, 6, 8, 36]
The study shows that of those who discontinued their prescribed injectable semaglutide or tirzepatide for obesity: The study, Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice, was published in the journal Obesity
Sharma M, Srivastava A, Fairfield HE, Bergstrom D, Flynn WF, Braun RE (2019) Identification of EOMES-expressing spermatogonial stem cells and their regulation by PLZF